白藜芦醇通过鞘氨醇激酶1途径抑制LPS诱导的肾小球系膜细胞增殖及TGF-β1表达

Your Location：

Home >

Browse articles >

白藜芦醇通过鞘氨醇激酶1途径抑制LPS诱导的肾小球系膜细胞增殖及TGF-β1表达

Original Article | Updated：2023-05-25

|

- 白藜芦醇通过鞘氨醇激酶1途径抑制LPS诱导的肾小球系膜细胞增殖及TGF-β1表达
- Inhibitory Effect of Resveratrol on LPS-Induced Glomerular Mesangial Cells Proliferation and TGF-β1 Expression via Sphingosine Kinase 1 Pathway
- 中国结合医学杂志（英文版） 2023年29卷第6期页码：500-507
- Affiliations：
  
  1.Department of Pharmacy, the Third Affiliated Hospital of Southern Medical University, Guangzhou (510630), China
  2.Department of Cardiology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou (310000), China
- Author bio：
  
  Prof. DENG Yan-hui, E-mail: shiningdyh@sina.com
- Funds：
  
  the National Natural Science Foundation of China(81603355;81900745)
- DOI：10.1007/s11655-022-3530-y
  中图分类号：
- 纸质出版日期：2023-06，
  
  网络出版日期：2022-03-08，
  
  录用日期：2021-10-08
Scan for full text
白藜芦醇通过鞘氨醇激酶1途径抑制LPS诱导的肾小球系膜细胞增殖及TGF-β1表达[J]. 中国结合医学杂志（英文版）, 2023,29(6):500-507.

FENG Fu-zhen, GONG Wen-yan, LI Si-yun, et al. Inhibitory Effect of Resveratrol on LPS-Induced Glomerular Mesangial Cells Proliferation and TGF-β1 Expression via Sphingosine Kinase 1 Pathway[J]. Chinese Journal of Integrative Medicine, 2023,29(6):500-507.
白藜芦醇通过鞘氨醇激酶1途径抑制LPS诱导的肾小球系膜细胞增殖及TGF-β1表达[J]. 中国结合医学杂志（英文版）, 2023,29(6):500-507. DOI： 10.1007/s11655-022-3530-y.

FENG Fu-zhen, GONG Wen-yan, LI Si-yun, et al. Inhibitory Effect of Resveratrol on LPS-Induced Glomerular Mesangial Cells Proliferation and TGF-β1 Expression via Sphingosine Kinase 1 Pathway[J]. Chinese Journal of Integrative Medicine, 2023,29(6):500-507. DOI： 10.1007/s11655-022-3530-y.

摘要

目的:

2

利用脂多糖(lipopolysaccharide

LPS)诱导的肾小球系膜细胞(glomerular mesangial cells

GMCs)模型

探讨白藜芦醇(resveratrol

RSV)影响鞘氨醇激酶1 (sphingosine kinase 1

SphK1)信号通路及其下游分子激活蛋白1(activator protein 1

AP-1)和转化生长因子-β1(transformation growth factor-β1

TGF-β1)的表达而发挥的肾脏保护作用.

方法:

2

将培养的大鼠 GMCs细胞株(HBZY-1)随机分为5组: 对照组、LPS (100 ng/mL)处理组和5、10、20 μmol/L RSV给药处理组

以SphK1抑制剂(SK-Ⅱ)作为阳性对照. 给药组GMCs先用相应浓度的RSV预处理2h

再使用LPS 处理24 h后用于后续实验. 采用3-(4

5-二甲基噻唑-2-基)-2

5-二苯基溴化四氮唑(MTT)比色法测定GMCs增殖情况

利用蛋白质印迹法(Western blot)测定GMCs中SphK1、p-c-Jun和TGF-β1蛋白表达水平

使用凝胶电泳迁移实验(EMSA)测定AP-1的DNA结合活性

采用AutoDock Vina模拟RSV与SphK1蛋白的结合方式并评估二者结合活性

使用Discovery Studio 2016进行可视化.

结果:

2

LPS能明显促进GMCs增殖

并增加SphK1、p-c-Jun和TGF-β1蛋白表达

提高AP-1的DNA结合活性(

P

<

0.05或

P

<

0.01)

而 RSV 预处理后能显著抑制这些作用

且与SK-II的抑制作用相似(

P

>

0.05). 此外

RSV与SphK1对接结合能为-8.1 kcal/mol

其与SphK1上ASP178和LEU268两个氨基酸残基形成氢键

表明二者具有较好的直接结合活性.

结论:

2

RSV抑制LPS诱导的GMCs增殖及TGF-β1表达进而延缓系膜细胞纤维化进展的作用可能不依赖于其降糖效应

而是与直接抑制SphK1通路密切相关.

Abstract

Objective:

2

To elucidate the renoprotective effect of resveratrol (RSV) on sphingosine kinase 1 (SphK1) signaling pathway and expression of its downstream molecules including activator protein 1 (AP-1) and transformation growth factor-β1 (TGF-β1) in lipopolysaccharide (LPS)-induced glomerular mesangial cells (GMCs).

Methods:

2

The rat GMCs line (HBZY-1) were cultured and randomly divided into 5 groups

including control

LPS (100 ng/mL)

and 5

10

20 μmol/L RSV-treated groups. In addition

SphK1 inhibitor (SK-Ⅱ) was used as positive control. GMCs were pretreated with RSV for 2 h and treated with LPS for another 24 h. GMCs proliferation was determined by 3-(4

5-dimethylthiazol-2-yl)-2

5-diphenyl tetrazolium bromide (MTT) assay. The proteins expression of SphK1

p-c-Jun and TGF-β1 in GMCs were detected by Western blot

and DNA-binding activity of AP-1 was performed by electrophoretic mobility shift assay (EMSA). The binding activity between RSV and SphK1 protein was detected by AutoDock Vina and visualized by Discovery Studio 2016.

Results:

2

LPS could obviously stimulate GMCs proliferation

elevate SphK1

p-c-Jun and TGF-β1 expression levels and increase the DNA-binding activity of AP-1 (

P

<

0.05 or

P

<

0.01)

whereas these effects were significantly blocked by RSV pretreatment. It was also suggested that the effect of RSV was similar to SK-Ⅱ (

P

>

0.05). Moreover

RSV exhibited good binding affinity towards SphK1

with docking scores of –8.1 kcal/moL and formed hydrogen bonds with ASP-178 and LEU-268 in SphK1.

Conclusion:

2

RSV inhibited LPS-induced GMCs proliferation and TGF-β1 expression

which may be independent of its hypoglycemic effect on preventing the development of mesangial cell fibrosis and closely related to the direct inhibition of SphK1 pathway.

关键词

Keywords

resveratrolglomerular mesangial cells proliferationsphingosine kinase 1 pathwaytransformation growth factor-β1molecular docking

references

Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004; 25:971-1010.

Migliorini A, Ebid R, Scherbaum CR, Anders HJ. The danger control concept in kidney disease: mesangial cells. J Nephrol 2013; 26:437-449.

Zhao JH. Mesangial cells and renal fibrosis. Adv Exp Med Biol 2019; 1165:165-194.

Meyer zu Heringdorf D, Jakobs KH. Renal mesangial cells: moving on sphingosine kinase-1. Br J Pharmacol 2007; 150:255-257.

Geoffroy K, Troncy L, Wiernsperger N, Lagarde M, El Bawab S. Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels. FEBS Lett 2005; 579:1249-1254.

Deng Y, Lan T, Huang J, Huang H. Sphingosine kinase-1/sphingosine 1-phosphate pathway in diabetic nephropathy. Chin Med J (Engl) 2014; 127:3004-3010.

Lan T, Liu W, Xie X, Xu S, Huang K, Peng J, et al. Sphingosine kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells. Mol Endocrinol (Baltimore, Md) 2011; 25:2094-2105.

Deng YH, Gong WY, Li Q, Wu X, Wu LY, Zheng XX, et al. Resveratrol inhibits high glucose-induced activation of AP-1 and NF-kappa B via SphK1/S1P2 pathway to attenuate mesangial cells proliferation and inflammation. J Funct Foods 2019; 55:86-94.

Chang AS, Hathaway CK, Smithies O, Kakoki M. Transforming growth factor-β1 and diabetic nephropathy. Am J Physiol Renal Physiol 2016; 310: F689-F696.

Shi GJ, Shi GR, Zhou JY, Zhang WJ, Gao CY, Jiang YP, et al. Involvement of growth factors in diabetes mellitus and its complications: a general review. Biomed Pharmacother 2018; 101:510-527.

Gellings Lowe N, Swaney JS, Moreno KM, Sabbadini RA. Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblasts. Cardiovasc Res 2009; 82:303-312.

Liu X, Hong Q, Wang Z, Yu Y, Zou X, Xu L. Transforming growth factor-β-sphingosine kinase 1/S1P signaling upregulates microRNA-21 to promote fibrosis in renal tubular epithelial cells. Exp Biol Med (Maywood) 2016; 241:265-272.

Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. Faseb J 2004; 18:816-827.

Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7: d793-d807.

Kitada M, Koya D. Renal protective effects of resveratrol. Oxid Med Cell Longev 2013; 2013:568093.

Den Hartogh DJ, Tsiani E. Health benefits of resveratrol in kidney disease: evidence from in vitro and in vivo studies. Nutrients 2019; 11:1624.

Kim MY, Lim JH, Youn HH, Hong YA, Yang KS, Park HS, et al. Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice. Diabetologia 2013; 56:204-217.

Gowd V, Kang Q, Wang Q, Wang Q, Chen F, Cheng KW. Resveratrol: evidence for its nephroprotective effect in diabetic nephropathy. Adv Nutr 2020; 11:1555-1568.

Flyvbjerg A. The role of the complement system in diabetic nephropathy. Nat Rev Nephrol 2017; 13:311-318.

Dalla Vestra M, Saller A, Mauer M, Fioretto P. Role of mesangial expansion in the pathogenesis of diabetic nephropathy. J Nephrol 2001; 14 Suppl 4: S51-S57.

Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis 2018; 71:884-895.

Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56:1761-1772.

Nymark M, Pussinen PJ, Tuomainen AM, Forsblom C, Groop PH, Lehto M. Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes. Diabetes Care 2009; 32:1689-1693.

Nan L, Huang M, Lai W, Jia R, Zheng Y, Yang L, et al. Impacts of the serum containing total flavonoids of Ajuga on rat glomerular mesangial cells. Mol Med Rep 2017; 16:4895-4902.

Alemany R, van Koppen CJ, Danneberg K, Ter Braak M, Meyer Zu Heringdorf D. Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol 2007; 374:413-428.

Gong W, Li J, Chen W, Feng F, Deng Y. Resveratrol inhibits lipopolysaccharide-induced extracellular matrix accumulation and inflammation in rat glomerular mesangial cells by SphK1/S1P2/NF-κB pathway. Diabetes Metab Syndr Obes 2020; 13:4495-4505.

Huang K, Huang J, Chen C, Hao J, Wang S, Huang J, et al. AP-1 regulates sphingosine kinase 1 expression in a positive feedback manner in glomerular mesangial cells exposed to high glucose. Cell Signal 2014; 26:629-638.

Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-E136.

Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001; 20:2390-2400.

Paugh BS, Bryan L, Paugh SW, Wilczynska KM, Alvarez SM, Singh SK, et al. Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. J Biol Chem 2009; 284:3408-3417.

Weigert C, Sauer U, Brodbeck K, Pfeiffer A, Häring HU, Schleicher ED. AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-beta1 promoter in mesangial cells. J Am Soc Nephrol 2000; 11:2007-2016.

Zhou P, Wan X, Zou Y, Chen Z, Zhong A. Transforming growth factor beta (TGF-β) is activated by the CtBP2-p300-AP1 transcriptional complex in chronic renal failure. Int J Biol Sci 2020; 16:204-215.

Beach JA, Aspuria PJ, Cheon DJ, Lawrenson K, Agadjanian H, Walsh CS, et al. Sphingosine kinase 1 is required for TGF-β mediated fibroblastto-myofibroblast differentiation in ovarian cancer. Oncotarget 2016; 7:4167-4182.

More>

0

浏览量

2

Downloads

0

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

相关文章

Therapeutic Mechanism of Kai Xin San on Alzheimer's Disease Based on Network Pharmacology and Experimental Validation

Mechanism of Key Ingredient of Astragalus membranaceus on Lung Adenocarcinoma via PI3K/AKT Signaling Clarified by Utilizing Network Pharmacology Approach and Experimental Validation

Resveratrol Modulates Bone Mineral Density and Bone Mineral Content in A Rat Model of Male Hypogonadism

In Silico Screening of Natural Products as Potential Inhibitors of SARS-CoV-2 Using Molecular Docking Simulation

Network Pharmacology-Based Exploration of Synergistic Mechanism of Guanxin Ⅱ Formula (冠心Ⅱ号方) for Coronary Heart Disease

相关作者

暂无数据

相关机构

The School of Basic Medical Sciences, Hubei University of Chinese Medicine

Key Laboratory of Cosmetics Monitoring and Evaluation, State Drug Administration, Shenzhen Institute for Drug Control

Faculty of Chinese Medicine and State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology

Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine

The Second Clinical Medical College, Guangzhou University of Chinese Medicine

⁰